S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial

This open-label, randomized phase II trial was performed to compare the efficacy and safety of nimotuzumab plus S-1 and cisplatin (NCS) versus S-1 and cisplatin (CS) alone in patients with untreated unresectable or metastatic gastric cancer in the first-line setting. Eligible participants were rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Feng, Zheng, Zhaoxu, Shi, SuSheng, Jiang, Zhichao, Qu, Tao, Yuan, Xinhua, Sun, Yongkun, Song, Yan, Yang, Lin, Zhao, Jiuda, Wang, Jinwan, Chi, Yihebali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616475/
https://www.ncbi.nlm.nih.gov/pubmed/26061330
http://dx.doi.org/10.1097/MD.0000000000000958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616475/
https://www.ncbi.nlm.nih.gov/pubmed/26061330
http://dx.doi.org/10.1097/MD.0000000000000958

Ejemplares similares